drugset / Trial / NCT03741712
A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The aim of this trial is to study the tolerance, pharmacokinetics (PK) and efficacy of SHR2554 alone or in combination with SHR3680 in the treatment of patients with metastatic Castration Resistant Prostate Cancer.
Timeline
- Start
- 2018-11-20
- Primary completion
- 2019-09-30
- Completion
- 2020-12-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rezvilutamide | Small molecule | 80 mg | Oral |
| Subject | SHR2554 | Small molecule | 50 mg | Oral |
| Subject | SHR2554 | Small molecule | 200 mg | Oral |